Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Obseva Sa (NQ: OBSV )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Obseva Sa

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Update on Board of Directors
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
From ObsEva SA
Via GlobeNewswire
Geneva Court Grants Temporary Moratorium to ObsEva
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
From ObsEva SA
Via GlobeNewswire
Organon Returns Ebopiprant to XOMA
From ObsEva SA
Via GlobeNewswire
ObsEva Files half Year 2023 Financial Statements
From ObsEva SA
Via GlobeNewswire
ObsEva Recovers Full Worldwide Rights on Nolasiban
From ObsEva SA
Via GlobeNewswire
Annual General Meeting 2023
From ObsEva SA
Via GlobeNewswire
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Change of Central Securities Depositary
From ObsEva SA
Via GlobeNewswire
ObsEva Files Year End 2022 Financial Statements
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Dismissal of Moratorium Proceedings
From ObsEva SA
Via GlobeNewswire
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
From ObsEva SA
Via GlobeNewswire
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
From ObsEva SA
Via GlobeNewswire
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Corporate Updates
From ObsEva SA
Via GlobeNewswire
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
From Organon
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.